Evaluate the clinical and economic burden of IgAN, including the limitations of symptom-directed/conventional therapies on patients, healthcare systems, and payers Analyze the efficacy, safety, and mechanisms of action of novel dual BAFF/APRIL B-cell directed therapies for the treatment of IgAN Develop strategies to enhance multidisciplinary care coordination and improve timely access to novel IgAN therapies
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 104 Windsor Center Drive
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedAug 31, 2026
-
Last day to claim creditSep 1, 2027 11 months left
-
Med Learning Group Optimizing Outcomes in nAMD: Evidence-Based Selection, Sequencing, and Durability Strategies with Next-Generation Anti-VEGF Therapies
-
PRIME Education, Inc. (PRIME®) Mock P&T: Applying the Latest Evidence to Advance Managed Care Decision-Making in Retinal Vascular Disease
-
Paradigm Medical Communications, LLC Reading Between the Lines: Nuanced Decision-Making With Sustained Delivery Therapies
-
HMP Education Reimagining Hidradenitis Suppurativa Care: Early Recognition, Therapeutic Innovation, and Multidisciplinary Care Across the Patient Journey
-
HMP Education CAR T-cell Therapy in ALL: Optimizing Selection, Sequencing, and Delivery in a Rapidly Evolving Landscape
-
HMP Education Transforming Psoriasis Care: Oral IL-23 Therapy and the Next Frontier in Patient-Centered Treatment
